Interestinghttps://clinicaltrials.gov/ct2/show/study/NCT04498117#contactlocation
Updated today; There's a 154 Locations recruting now.
They need 602 subjects: For Cohort 1 - Primary Surgery, 372 subjects randomized in a 1:1 ratio (i.e., chemotherapy with oregovomab or chemotherapy with placebo). For Cohort 2 - NACT + Interval Surgery, 230 subjects will be randomized in a 1:1 ratio (i.e., chemotherapy with oregovomab or chemotherapy and placebo).